))
NSAIDs, Part 3: The rise, fall and rise again of COX-2 inhibition
Manage episode 436874438 series 3560282
Innehåll tillhandahållet av Healio, Adam J. Brown, and MD. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Healio, Adam J. Brown, and MD eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?
- Intro 0:11
- Recap of part 1 & 2 0:28
- In this episode 1:44
- Cyclooxygenase 2 (COX-2) and the rat experiment 3:12
- What do we know about the prostaglandins? And what about COX-2 7:54
- What does prostacyclin do? 10:33
- The first COX-2 inhibitor: VIOXX 10:56
- What is COX-2 doing?: Pfizer and Merck 12:15
- Two more NSAID studies: colon cancer, Alzheimer’s disease and COX-2 inhibitors 18:41
- VIOXX: Why is myocardial infarction risk occurring? 22:34
- Animal models and the Goldilocks theory of thromboxane and prostacyclin 23:49
- PRECISION trial 30:25
- Rheum + Boards 37:14
- Thanks for listening 37:32
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
References:
Anderson GD, et al. J Clin Invest. 1996;doi:10.1172/JCI118717.
Funk CD, et al. J Cardiovasc Pharmacol. 2007;doi:10.1097/FJC.0b013e318157f72d.
Hennan JK, et al. Circulation. 2001;doi:10.1161/hc3301.092790.
Krumholz HM, et al. BMJ. 2007;doi:10.1136/bmj.39024.487720.68.
Nissen SE, et al. N Engl J Med. 2016;doi:10.1056/NEJMoa1611593.
Disclosures: Brown reports no relevant financial disclosures.
83 episoder
Dela
